Reduction of drug prices due to customs duty concession on intermediates

911. SHRIMATI KAILASHPATI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 715 given in the Rajya Sabha on the 14th May, 1990 and state:

(a) whether it is a fact that prices of none of the end products have been reduced consequent to customs duty reduction on the 20th March, 1990;

(b) whether it is also a fact that customs duty on end products consequent to customs duty concessions granted earlier was also not reduced;

(c) whether it is a fact that loss to exchequer has taken place without any benefit to consumer;

(d) what are the names of drugs whose prices have been reduced on account of duty concessions granted on inputs and intermediates; and

(e) what was earlier and present price of each?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) No, Sir.

(b) No, Sir. The prices of several price controlled bulk drugs were revised based on customs duty reductions effected before 20th March, 1990.

(c) Does not arise.

(d) and (e) Price of Doxycycline have been reduced from Rs. 5456 per kg. to Rs. 4,968 per kg. with effect from 9-8-90. There is no reduction in the price of Chloromphenicol even after customs duty reduction due to increase in the international price of L-Base.

Cash Compensatory Support to drugs and intermediates

912. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the names of drugs and intermediates which have been recommended for Cash Compensatory Support to the Ministry of Commerce during the last three years, year-wise;

(b) what is the rate of Cash Compensatory Support recommended for each and what are the details of basis on which each recommendation was made; and

(c) what has been the export of drugs and the intermediates in question during the last three years, year-wise?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) to (c) The information is being collected and will be laid on the Table of the House.

Appointment of Chairman/Managing Director in Indian Airlines and Air India

913. SHRI SURESH KALMADI: Will the Minister of CIVIL AVIATION be pleased to state:

(a) what is the reasons for which the Boards of Indian Airlines and Air India have been packed with Government officials; and

(b) what is the time-frame for the appointment of the Chairman/Managing Director of Indian Airlines and Air India?

THE MINISTER OF ENERGY WITH ADDITIONAL CHARGE OF THE MINISTRY OF CIVIL AVIATION (SHRI ARIF MOHD. KHAN): (a) The Boards of the two Corporations will soon be expanded with the appointment of non-officials.

(b) Steps are being taken for the appointment of Chairman and Managing Director of the two Corporations on a regular basis.

Service-bility of aircrafts with Vayudoot

914. SHRI SURESH KALMADI: Will the Minister of CIVIL AVIATION be pleased to state:

(a) what is the service-bility of various types of aircraft with the Vayudoot; and

(b) what is the state of the Dornier aircraft in the Vayudoot fleet?

THE MINISTER OF ENERGY WITH ADDITIONAL CHARGE OF THE MINISTRY OF CIVIL AVIATION (SHRI ARIF MOHD. KHAN): (a) and (b) Vayudoot's fleet consists of 10 numbers HS-748, 2 numbers F-27 and 8 numbers DO-228 aircraft. As on date 5 numbers HS-748, one number F-27 and 8 numbers DO-228 are serviceable.

Review of overcharged amounts on Glybenclamide

915. SHRI SYED SIBTEY RAZI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Starred Question 68 given in the Rajya Sabha on the 14th May, 1990 and state:

(a) what is the period for which the liability was to be assessed against Glybenclamide as per the order of Supreme Court;

(b) what are the reasons for which the Special Team assessed the liability only from the 17th November to 31st December, 1983;

(c) what steps have been taken to assess the liability upto the required period;

(d) whether it is a fact that he has ordered a review in the matter;

(e) if so, what is the outcome thereof;

(f) whether it is also a fact that a decision has been taken to remove this drug from price decontrolled list; and

(g) if so, by when the drug would be included under price control?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) to (c) The liability was required to be assessed from 17th November, 1983 upto 25th August, 1987 as per the orders of the Supreme Court, and the same is being done accordingly, in two phases.

(d) and (e) Review undertaken so far is based on the available data. The amounts so assessed would undergo further changes once the complet details are made available by the companies involved in the Supreme Court case. A Statement showing the revision in tentatively assessed amounts after such a review is attached. *(See* below)

(f) and (g) A number of representations were received against the decontrol of bulk drug Glybenclamide. The matter has been considered by the Standing Committee set up by the Government to consider anomalies in the findings of the Kelkar Committee. The recommendations of the Committee are receiving attention.

Statement

(Rs. in lakhs)

S.No.	Name of the Company	Tentative amount assessed by the Special Team upto 31-12-1983	Tentative amount assessed upto 31-12-1983 after review
1.	M/s. Pfizer Limited	48.21	87.61
2.	M/s. Cyanamid India Ltd.	385.06	536.91
3.	M/s. Hoechst (India) Ltd.	458.10	2491.05
4.	M/s. Anil Starch Products Ltd.	11.61*	11.61
5.	M/s. John Wyath (India Ltd. M/s. Geoffrey Manners	133.45 28.37	173.02 28.37
6.	M/s. Ethnor Limited	8.15	10.19
7.	M/s. S.G. Pharmaceuticals	114.30*	205.36
8.	M/s. Tamil Nadu Dadha Pharmaceuticals Ltd.	15.59*	37.97
9.	M/s. Merind Ltd.	138.79*	781.58
10.	M/s. Franco Indian Pharmaceuticals Ltd. M/s. Griffon Ltd.	11.02	14.02

*Assessed but not communicated to the company.